Key result
Taking over five medications is linked to ~6.5-fold higher drug-drug interaction risk in kidney transplant patients.
Why the study?
Chronic kidney disease is linked with polypharmacy and complex medication regimens, putting patients at risk for potential drug-drug interactions.
What is the prevalence and clinical significance of potential drug-drug interactions in end-stage renal disease patients?
Observational (n=96)
No
What is the prevalence and clinical significance of potential drug-drug interactions in end-stage renal disease patients?
p-value: p=<0.001
Potential drug-drug interactions are highly prevalent in end-stage renal disease patients, underscoring the need for careful medication management and multidisciplinary review in this polypharmacy-prone population.
High pDDI prevalence in renal transplant polypharmacy warrants vigilance; observational data leaves open effects on clinical outcomes.
Background and Objectives: Chronic kidney disease (CKD) is usually linked with polypharmacy and patients are invariably at risk of complex medication regimens. The present study was designed to estimate the potential drug-drug interactions (pDDIs) through the prescription patterns provided to patients of the Nephrology Transplant Unit of Cerrahpasa Medical Faculty patients. Materials and Methods: 96 patients were included in the study. pDDIs among every combination of the prescribed drug were analyzed using the Thomson Reuters Micromedex. Results: We found 149 pDDIs making 2.16 interactions per prescription with incidence rates of 69.7%. Approximately 4.1% of interactions were of significant severity, 75.1% moderate severity, and 20.8% were classified as minor pDDIs. The most frequent interactions were found between iron and aluminum, calcium or magnesium-containing products (21.37%), calcium channel blockers and beta-blockers (8.96%); and aspirin and aluminum, calcium, or magnesium-containing products (7.58%). We identified 42 drug pairs with probability of clinical significance. The most commonly reported clinical outcomes of the pDDIs were hypo- or hypertension (39.24%), decreased drug efficacy (24.05%), and arrhythmia (9.49%). Aluminum, calcium, or magnesium-containing drug products (33.10%) constituted the primary class of drugs involved in interactions. Conclusions: This study showed pharmacodynamics (49%), pharmacokinetics (42.94%) interactions, polypharmacy and gender as determinant of pDDIs. A comprehensive multicenter research is required to decrease the morbidity and ease the state burden.
No takes yet. Share an insight, caveat, or question.
Shahzadi et al. (2022) conducted an observational in End-stage renal disease (ESRD) (n=96). Polypharmacy / Prescribed medication regimens was evaluated on Prevalence of potential drug-drug interactions (pDDIs) (p=<0.001). Potential drug-drug interactions were identified in 69.7% of end-stage renal transplant patients, with the risk significantly increased in those taking more than five medications (OR 6.52).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: